Next Stage One: Leveraging Seed Capital to Deliver Precision Antiparasitics

With resistance to existing parasiticides rising and few new molecules in decades, ASTRA Therapeutics set out to change the game. Co-CEOs Natacha Gaillard and Ashwani Sharma share how the company closed one of the largest seed rounds in animal health, positioned itself to deliver precision-designed antiparasitics, and built investor confidence in solving one of animal health’s most urgent challenges.